Search

Your search keyword '"Thiede, Christian"' showing total 1,640 results

Search Constraints

Start Over You searched for: Author "Thiede, Christian" Remove constraint Author: "Thiede, Christian"
1,640 results on '"Thiede, Christian"'

Search Results

1. Rearrangements involving 11q23.3/KMT2A in adult AML: mutational landscape and prognostic implications – a HARMONY study

2. Recommendations from the AML molecular MRD expert advisory board

3. Epigenetic alterations affecting hematopoietic regulatory networks as drivers of mixed myeloid/lymphoid leukemia

4. Mimicking clinical trials with synthetic acute myeloid leukemia patients using generative artificial intelligence

6. Prognostic impact of CEBPA mutational subgroups in adult AML

7. Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia

8. Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European LeukemiaNet risk classification

9. Activation of distinct inflammatory pathways in subgroups of LR-MDS

10. UBTF tandem duplications are rare but recurrent alterations in adult AML and associated with younger age, myelodysplasia, and inferior outcome

11. Unsupervised meta-clustering identifies risk clusters in acute myeloid leukemia based on clinical and genetic profiles

12. Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcome

17. Large case-control study indicates no association of KIR genotype and risk of developing acute myeloid leukemia

18. Retained functional normal and preleukemic HSCs at diagnosis are associated with good prognosis in DNMT3AmutNPM1mut AMLs

19. Prospective validation of a biomarker-driven response prediction model to romiplostim in lower-risk myelodysplastic neoplasms – results of the EUROPE trial by EMSCO

21. Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial

22. Overlapping features of therapy-related and de novo NPM1-mutated AML

23. The DKTK EXLIQUID consortium – exploiting liquid biopsies to advance cancer precision medicine for molecular tumor board patients

26. Deep learning identifies Acute Promyelocytic Leukemia in bone marrow smears

27. Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation

28. Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations

31. Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study

32. Lipidomic approach for stratification of Acute Myeloid Leukemia patients

33. CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome

35. Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results

37. Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia

39. Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial

40. Hotspot DNMT3A mutations in clonal hematopoiesis and acute myeloid leukemia sensitize cells to azacytidine via viral mimicry response

41. Prognostic impact of CEBPA mutational subgroups in adult AML

43. Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial

44. VEXAS Syndrome: Complete molecular remission after hypomethylating therapy

45. Mimicking Clinical Trials with Synthetic Acute Myeloid Leukemia Patients Using Generative Artificial Intelligence

46. The clinical mutatome of core binding factor leukemia

47. Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents

48. Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial

50. Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower‐intensity therapy: Roadmap from an ELN‐DAVID expert panel

Catalog

Books, media, physical & digital resources